StockNews.AI
IDYA
StockNews.AI
219 days

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

1. IDEAYA to present corporate updates at J.P. Morgan Healthcare Conference. 2. 2025 corporate guidance includes updated financial projections. 3. Company focuses on targeted therapeutics using molecular diagnostics. 4. They emphasize synthetic lethality as a precision medicine target.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive corporate guidance can boost investor confidence and share price. Other companies in healthcare see similar boosts post-conference presentations.

How important is it?

The corporate guidance is crucial for future performance predictions. Direct updates can reshape market perceptions about IDYA.

Why Short Term?

Immediate interest may arise from the conference presentation. Past events show quick reactions post-announcements.

Related Companies

IDYANASDAQ
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates. 43rd Annual J.P. Morgan Healthcare ConferenceMonday, January 13th, 2025, at 5:15 PM PT (8:15 PM ET) 2025 Corporate Guidance to be Presented at the 43rd Annual J.P. Morgan Healthcare Conference: IDEAYA's updated JPM 2025 corporate presentation reflecting its 2025 corporate guidance is available on its website under the Investor Relations section: https://ir.ideayabio.com/. A live audio webcast of the presentation and Q&A session will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to (i) participation in and/or presentation at certain investor relations events and (ii) 2025 corporate guidance regarding the extent to which IDEAYA's existing cash, cash equivalents, and marketable securities will fund its planned operations and (iii) program updates regarding the potential timing of various activities. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 20, 2024. Investor and Media ContactIDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor Relations[email protected] SOURCE IDEAYA Biosciences, Inc.

Related News